Category: MedifocusSyndicate content

Medifocus brings in $3.5M via debt financing

December 19, 2013 by Chris Walker

Medifocus raises $3.5 million through a convertible debt financing round, part of the company's private stock offering.

Medifocus brings in $3.5M in convertible debt financing

Medifocus (PINK:MDFZF) said it brought in $3.5 million in a private offering of convertible debt, a raise tied to company's August non-brokered private placement of $6 million.

Second Sight eyes $10M funding round | Wall Street Beat

July 25, 2013 by Brad Perriello

Second Sight Medical registers for a $10 million funding round to back its Argus II 'bionic eye' retinal implant. Wall Street Beat

Second Sight Medical is hoping to raise $10.5 million, according to a regulatory filing, as it brings its "bionic eye" Argus II retinal implant to the U.S. market.

The device, comprised of an eyeglass-mounted camera and an electrical stimulator implanted in the eye, works by converting video images captured by a miniature camera housed in the patient's glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes on the surface of the retina.

Boston Scientific sells Prolieve device back to Medifocus for $5M

June 27, 2012 by MassDevice staff

Boston Scientific sells the Prolieve benign prostatic hyperplasia treatment system back to Medifocus in a deal worth up to $5 million.

Updated June 28, 2012, at 12:45 p.m. with comments from Medifocus.


Medical device titan Boston Scientific (NYSE:BSX) sold the Prolieve business back to Medifocus (PINK:MDFZF) in a deal valued at $5 million.

Report: J&J set for EU OK on Synthes buyout | Wall Street Beat

March 19, 2012 by MassDevice staff

European Union regulators are ready to OK Johnson & Johnson's $21.3 billion buyout of Synthes; also, Study: Patent-sharing the rising tide that lifts all boats; Standard & Poor's boosts CareFusion rating; Delcath inks Spanish training deal; Kozlowski is back in New York; DoD exercises option on $71M Zimmer contract; PE firm prepping for Medidata takeover?; C-level shifts at Alphatec prompt NASDAQ warning; PositiveID taps investor relations shop Trilogy Capital; plus, a Funding Roundup and analysts' ups and downs. Wall Street Beat

European Union regulators are poised to give the OK to Johnson & Johnson's (NYSE:JNJ) $21.3 billion acquisition of Swiss orthopedic giant Synthes, according to Reuters.